Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the data from the Phase I/II trials evaluating camonsertib (RP-3500/RG6526, partnered with Roche) in combination with three poly (ADP-ribose) polymerase inhibitors (PARPi) has been selected for the clinical plenary session at the 2023 AACR Annual Meeting, held April 14-19, 2023, in Orlando, Florida. An AACR assigned discussant of the presentation will interpret the data in this plenary session. Two poster presentations for RP-6306, a first-in-class, oral PKMYT1 inhibitor, will also be introduced in the Clinical Research session.
Details for the presentations are as follows:
Title: Safety and efficacy of three PARP inhibitors (PARPi) combined with the ataxia telangiectasia- and Rad3-related kinase inhibitor (ATRi) camonsertib in patients (pts) with solid tumors harboring DNA damage response (DDR) alterations
Presenter: Dr. Timothy Yap
Session Category: Clinical Trials Plenary Session
Session Title: Novel Biomarker-driven Molecularly Targeted Therapy Trials
Date and Time: Tuesday Apr 18, 2023 11:15 AM - 11:30 AM
Published Abstract Number: 23-LB-9625-AACR
Title: Characterization of CCNE1 amplifications and associated genomic features in ovarian and uterine cancers
Session Category: Clinical Research Excluding Trials
Session Title: Biomarkers of Therapeutic Benefit 5
Date and Time: Tuesday Apr 18, 2023 1:30 PM - 5:00 PM
Location: Poster Section 37
Poster Board Number: 19
Published Abstract Number: 5469
Title: Tumor heterogeneity of CCNE1 copy number assessed by fluorescence in situ hybridization (FISH) in ovarian and uterine cancers and correlation with cyclin E protein expression
Session Category: Clinical Research Excluding Trials
Session Title: Biomarkers of Therapeutic Benefit 2
Date and Time: Monday Apr 17, 2023 9:00 AM - 12:30 PM
Location: Poster Section 39
Poster Board Number: 6
Published Abstract Number: 2132
About Repare Therapeutics’ SNIPRx® Platform
Repare’s SNIPRx® platform is a genome-wide CRISPR-based screening approach that utilizes proprietary isogenic cell lines to identify novel and known synthetic lethal gene pairs and the corresponding patients who are most likely to benefit from the Company’s therapies based on the genetic profile of their tumors. Repare’s platform enables the development of precision therapeutics in patients whose tumors contain one or more genomic alterations identified by SNIPRx® screening, in order to selectively target those tumors in patients most likely to achieve clinical benefit from resulting product candidates.
About Repare Therapeutics, Inc.
Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes RP-6306, a PKMYT1 inhibitor currently in Phase 1 clinical development; camonsertib (also known as RP-3500 or RG6526), a potential leading ATR inhibitor currently in Phase 1/2 clinical development and partnered with Roche; a preclinical Polθ inhibitor program; as well as several additional, undisclosed preclinical programs. For more information, please visit reparerx.com.
SNIPRx® is a registered trademark of Repare Therapeutics Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005911/en/
